Wilms tumor 1 (WT1) is a promising target of new immunotherapies for extreme myeloid leukemia (AML) while well while for other cancers. were observed during the study. Immunological reactions were observed in OCV-501-specific delayed-type hypersensitivity test. This trial was authorized at http://www.clinicaltrials.gov while “type”:”clinical-trial”,”attrs”:”text”:”NCT 01440920″,”term_id”:”NCT01440920″NCT 01440920. Electronic extra material The online version of this article… Continue reading Wilms tumor 1 (WT1) is a promising target of new immunotherapies